PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks

Abstract

PURPOSE An online clinical information system, called Predictive Research Online System Prostate Cancer Tasks (PROSPeCT), was developed to enable users to query the Alberta Prostate Cancer Registry database hosted by the Alberta Prostate Cancer Research Initiative. To deliver high-quality patient treatment, prostate cancer clinicians and researchers require a user-friendly system that offers an easy and efficient way to obtain relevant and accurate information about patients from a robust and expanding database. METHODS PROSPeCT was designed and implemented to make it easy for users to query the prostate cancer patient database by creating, saving, and reusing simple and complex definitions. We describe its intuitive nature by exemplifying the creation and use of a complex definition to identify a “high-risk” patient cohort. RESULTS PROSPeCT was made to minimize user error and to maximize efficiency without requiring the user to have programming skills. Thus, it provides tools that allow both novice and expert users to easily identify patient cohorts, manage individual patient care, perform Kaplan Meier estimates, plot aggregate PSA views, compute PSA-doubling time, and visualize results. CONCLUSION This report provides an overview of PROSPeCT, a system that helps clinicians to identify appropriate patient treatments and researchers to develop prostate cancer hypotheses, with the overarching goal of improving the quality of life of patients with prostate cancer. We have made available the code for the PROSPeCT implementation at https://github.com/max-uhlich/e-PROSPeCT .

Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients

“…The selection of mCRPC patients was principally based on antiandrogen therapy with serum samples collected either pre-or post-antiandrogen therapy using PROSPeCT, a Predictive Research Online System for Prostate Cancer Tasks. 67 Our study includes patients treated with either enzalutamide, abiraterone, or both therapies (Table S2). 5 Age at diagnosis ranges from 55 to 87 years, with broad PSA levels ranging from 2.4 to 135.5 ng mL −1 , and Gleason scores at diagnosis ≥ 7 indicative of poor prognosis.…”

“…We analyzed seven mCRPC patients (identifiers #46, #102, #112, #123, #1667, #2825, and #2848) and two healthy male controls (identifiers S and D). The selection of mCRPC patients was principally based on antiandrogen therapy with serum samples collected either pre- or post-antiandrogen therapy using PROSPeCT, a Predictive Research Online System for Prostate Cancer Tasks . Our study includes patients treated with either enzalutamide, abiraterone, or both therapies (Table S2).…”

Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada

“…The APCaRI Registry data are queried, compared, analysed and visualised using the Predictive Research Online System for Prostate Cancer Tasks (PROSPeCT); APCaRI’s user-friendly online Clinical Information System. 17 …”

“…The APCaRI Registry data are queried, compared, analysed and visualised using the Predictive Research Online System for Prostate Cancer Tasks (PROSPeCT); APCaRI's user-friendly online Clinical Information System. 17 Blood, urine and/or semen biospecimens are collected at baseline and annually for 5 years as well as at points of PCa disease status changes according to APCaRI standard operating procedures (SOPs; tables 1 and 2). Blood samples are clotted as applicable, centrifuged and aliquoted into serum, plasma, buffy coat and red blood cells.…”